Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Explore Private Companies / Escient Pharmaceuticals IPO

Escient Pharmaceuticals IPO

escientpharma.comHealthcare / BioTech & Pharma

Escient Pharmaceuticals is a biotech company specializing in the treatment of neurosensory-inflammatory disorders. Escient’s therapeutic programs apply state-of-the-art chemistries and biological understanding for its highly differentiated treatments using a novel class of cellular receptors called Mass-related G protein-coupled receptors (MRGPRS) that can detect and target a broad range of neuro-diseases.

Learn more about Escient Pharmaceuticals stock
Register for Details

For more details on financing and valuation for Escient Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Escient Pharmaceuticals

Forge green plus iconForge green minus icon

What is Escient Pharmaceuticals's funding to date?

Escient Pharmaceuticals has raised $243.51MM to date.
Forge green plus iconForge green minus icon

When was Escient Pharmaceuticals founded?

Escient Pharmaceuticals was founded in 2015.

Who are Escient Pharmaceuticals's major investors?

Cowen Group
Perceptive Advisors
Redmile Group
Sanofi Genzyme BioVentures
Osage Partners
The Column Group
Altitude Life Science Ventures
NEA

Escient Pharmaceuticals funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
11/28/2022

Series C

 $120MM raised $XXX.XX $XXX.XX
9/14/2020

Series B

 $82.96MM raised $XXX.XX $XXX.XX
5/9/2018

Series A

 $40.55MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Private companies exploring an IPO

Cerebras
Sector
Technology Hardware / Computing hardware
Last Round Est. Valuation
$2.87B
CoreWeave
Sector
Enterprise Software / Data Intelligence
Last Round Est. Valuation
$19B
Liquid Death
Sector
FoodTech / Food Products & Services
Last Round Est. Valuation
$1.4B
Vuori
Sector
Consumer & Lifestyle / Clothing, Fashion, Beauty & Apparel
Last Round Est. Valuation
$213.97MM
Cohesity
Sector
Enterprise Software / Data Management/​Storage
Last Round Est. Valuation
$3.4B
Klarna
Sector
FinTech / Lending
Last Round Est. Valuation
$5.41B
Chime
Sector
FinTech / Digital Banking
Last Round Est. Valuation
$24.93B
SKIMS
Sector
Consumer & Lifestyle / Clothing, Fashion, Beauty & Apparel
Last Round Est. Valuation
$4B
See the IPO Calendar
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.